OrthoPediatrics Into Earnings With Sellers Retreating and Options Turning Defensive

OrthoPediatrics Corp. heads into its Monday earnings release with a stock that has rallied sharply, insiders who have been trimming aggressively, and options traders who have just started to hedge.

The most arresting detail this week is the insider register. Squadron Capital, the company's largest holder at roughly 24% of shares, has been a consistent seller since late August. Together with director David R. Pelizzon, who is also a 10% owner filing under Schedule 13D, and Jennifer Pritzker, the group sold more than 660,000 shares across multiple tranches in September alone. The largest single block, 326,700 shares from Squadron Capital on August 28, went out at $23.04. The combined net insider position over the past 90 days is negative 2.1 million shares, with proceeds of nearly $47 million. None of the trades were flagged as being executed under a 10b5-1 pre-arranged plan. That distinction matters: discretionary selling at these volumes, from the stock's controlling shareholder-director cluster, is a harder signal to dismiss than routine plan-driven liquidations. Squadron's institutional holding as last reported still stood at 6.2 million shares, so they remain heavily invested. But the direction of travel is clearly outward, and the pace accelerated as the stock recovered toward current levels near $24.50.

The activist register reinforces the picture. Pelizzon filed a Schedule 13D/A in September disclosing his stake had fallen from 25.2% to 23.9%. ORTEX's activist data confirms a 13D filer is on the register, which is ordinarily a sign of engaged, change-oriented ownership. Here the filing reflects a reduction rather than accumulation, which complicates the usual interpretation. Millennium Management also filed a 13G/A in July showing its stake had dropped from 5.5% to 3.2%. As a general caveat, 13D/G positions are event-driven disclosures around the 5% threshold and holders can fall further without filing again.

The lending market offers no evidence that bearish sentiment is building in parallel. Availability is extremely loose, running at 1,476%, meaning there are roughly 14 shares available to borrow for every one already lent out. Borrowing costs have fallen sharply too, now at just 0.50% against a recent mid-October peak above 2%. Short interest itself is modest at 3.5% of free float and has edged down 2.6% on the week. None of these signals point to a coordinated short-side bet against the stock. The ORTEX short score has drifted lower from 43.4 two weeks ago to 41.1 now, consistent with reduced short conviction rather than any squeeze dynamic. Where the positioning picture does get more interesting is options. The put/call ratio closed at 0.44 on Thursday, nearly two standard deviations above its 20-day average of 0.25. That is the most defensive options setup KIDS has seen in recent weeks, landing just below the 52-week high (which was a brief spike to 20.8 on an illiquid day and can be treated as an outlier). The timing, three trading days before earnings, suggests investors are buying downside protection into the print rather than expressing structural bearishness.

The Street remains broadly constructive. The consensus is Buy, with a mean price target of $27.50 against Friday's close of $24.50, implying roughly 12% upside. BTIG reiterated its Buy and $29 target in mid-September. Needham lifted its target from $30 to $35 after the Q2 report in early August, the most bullish posture among named analysts. Piper Sandler and Truist are also active; Truist sits at Hold with a $20 target, the clear outlier. Bulls point to OrthoPediatrics' product "Super Cycle," with launches across trauma, deformity, and scoliosis categories driving 13.3% revenue growth in Q1 2026 and full-year guidance of $263 million to $267 million. Bears flag execution risk, distributor dependency, and the absence of positive earnings, a picture reflected in the PE multiple of negative 31.5x and an EPS momentum score that ranks in just the 10th percentile on a 30-day basis. The sector score, at the 88th percentile, remains the strongest factor on the board, suggesting the company continues to benefit from favorable industry positioning even as its own earnings trajectory lags.

Ownership is concentrated in ways that bear watching. Brown Advisory added 161,000 shares in the quarter to September, and Granahan Investment Management added 189,000. Wasatch Advisors added 185,000. The buying from these three active managers over the same period that Squadron was selling is notable: professional long-only money has been on the other side of the insider trade. The stock is up 11.6% on the week going into the report, compared to a 2.2% gain for close peer ICUI and a 12.5% gain for BVS, suggesting KIDS is moving on its own dynamic rather than riding a sector tide.

The last two earnings events both produced positive one-day moves, the most recent print in August delivered a 6.9% gain on the day and 16.1% over the following five sessions. The question going into Monday is whether that pattern holds, given that the stock has already re-rated meaningfully in the run-up, insiders have been net sellers throughout the recovery, and options traders have just started adding protection.